Name: Monil Dharod

Class: T.Y.BMS
Subject: Entrepreneurship
Management
Entrepreneur: Kiran
Mazumdar Shaw
(Chairman & M.D of Biocon
Limited)
What is Entrepreneur?
The word entrepreneur originates from the French word,
entreprendre, which means "to undertake." In a business context, it
means to start a business. The Merriam-Webster Dictionary
presents the definition of an entrepreneur as one who organizes,
manages, and assumes the risks of a business or enterprise.
Entrepreneur a person, who has initiative in investment and
decision to the enterprise; seeking all resource of factor of
production, resources of Management, Behavior, Cultural,
Economical and Political factor for establishing, innovation and
founded enterprise, having assumption of risk, profit and future
growth.
According to A Schumpeter “The entrepreneurship is essentially a
creative activity or it is an innovative function”.
According to Michael Gerber “The entrepreneur is our visionary,
the creator in each of us. We're born with that quality and it defines
our lives as we respond to what we see, hear, feel, and experience.
It is developed, nurtured, and given space to flourish or is
squelched, thwarted, without air or stimulation, and dies.”

Entrepreneur Quotes
"An entrepreneur tends to bite off a little more than he can chew
hoping he'll quickly learn how to chew it." - Roy Ash
"In the modern world of business, it is useless to be a creative,
original thinker unless you can also sell what you create." - David
Ogilvy

“The entrepreneur always searches for change, responds to it, and

exploits it as an opportunity” - Peter Drucker

Kiran Mazumdar Shaw

(Chairman & M.D of Biocon
Limited)
Profile
Kiran Mazumdar Shaw was born on March 23, 1953 in Bangalore. She had
her schooling at Bishop Cotton Girls School and Mount Carmel College at
Bangalore. After doing completing her B.Sc. in Zoology from Bangalore
University in 1973, she went to Ballarat University in Melbourne, Australia
and qualified as a master brewer. She also worked for some time as a
Technical Consultant at Jupiter Breweries Limited, Calcutta and as a
Technical Manager at Standard Maltings Corporation, Baroda between 1975
and 1977.

She is married to John Shaw, a Scotsman and Indophile, who headed a

leading textiles MNC, Madura Coats from 1991-1998 as Chairman and
Managing Director. John Shaw is currently the Vice-Chairman, Biocon
Limited.

Kiran Mazumdar-Shaw is a connoisseur of art and has a huge collection of

paintings and other works of art in her possession. She is the author of a
coffee table book, Ale & Arty: The Story of Beer.

As a civic activist, she has been involved in various programs to improve the
city of Banglaore, such as the Bangalore Agenda Task Force (BATF).

Kiran Mazumdar-Shaw is a member of the Governing Body and General

Body of the Indian Pharmacopoeia Commission, an autonomous body of the
Government of India. She is a founder member of the Society for the
formation of the Institute for Stem Cell Biology and Regenerative Medicine.
She has also been nominated as Member of the Board of Trade, Directorate
General of Foreign Trade, Ministry of Commerce & Industry.

She is a member of the National Innovation Council, Government of India,

and a member of the Board of Governors, Indian Institute of Management,
Bangalore. She is also a member of the Science and Engineering Research
Council (SERC), Ministry of Science & Technology, Government of India,
and a Board Member, BIO Ventures for Global Health, and the Honorary
Consul, Irish Embassy in Karnataka.

She was recently named among TIME magazine’s 100 most influential
people in the world. She is also on the Forbes list of the world’s 100 most
powerful women, and the Financial Times’ top 50 women in business list.

.Business: Biocon Biochemicals Limited

In 1978, she joined as Trainee Manager with Biocon Biochemicals Limited

in Ireland. In the same year, Kiran Mazumdar Shaw founded Biocon India in
collaboration with Biocon Biochemicals Limited, with a capital of
Rs.10,000.
Initially, she faced credibility challenges because of her youth, gender and
her untested business model. Not only was funding a problem as no bank
wanted to lend to her, but she also found it difficult to recruit people for her
start-up. With single-minded determination she overcame these challenges
only to be confronted with the technological challenges associated with
trying to build a biotech business in a country facing infrastructural woes.
Uninterrupted power, superior quality water, sterile labs, imported research
equipment, and advanced scientific skills were not easily available in India
during the time. She took the challenges in her stride and worked within the
limiting circumstances to take Biocon to newer and greater heights.

She is quoted as saying, “Success is about pursuing a vision with a sense of

purpose and a spirit of challenge. There are no short cuts to success and
there is no substitute for hard work. I also believe success is about doing
things in a differentiated way - dare to be different so that you stand out.
Biocon's byline is ‘The difference lies in our DNA’ and we all believe in it.
We don't imitate other companies but have charted our own business
destiny.”

She is responsible for steering Biocon on a trajectory of growth and

innovation over the years. Within a year of its inception, Biocon became the
first Indian company to manufacture and export enzymes to USA and
Europe.

In 1989, Biocon became the first Indian biotech company to receive US

funding for proprietary technologies.

In 1990, she upgraded Biocon’s in-house research program, based on a

proprietary solid substrate fermentation technology. The commercial success
of this program led to a three-fold expansion by 1996 and Biocon entered the
biopharmaceuticals and statins segments.

In 1997, she undertook initiatives in human healthcare through a dedicated

manufacturing facility.

In 1998, when Unilever agreed to sell its shareholding in Biocon to the

Indian promoters, Biocon became an independent entity. Two years later,
Biocon's proprietary bioreactor, christened PlafractorTM, based on solid
matrix fermentation received a U.S. patent and Kiran Mazumdar-Shaw
commissioned Biocon’s first fully automated submerged fermentation plant
to produce specialty pharmaceuticals.
By 2003 Biocon became the first company worldwide to develop human
insulin on a Pichia expression system.

In the same year, she incorporated Biocon Biopharmaceuticals Private

Limited to manufacture and market a select range of biotherapeutics in a
joint venture with the Cuban Centre of Molecular Immunology.

In 2004, she decided to access the capital markets to develop Biocon’s

pipeline of research programs. Biocon’s IPO was oversubscribed 32 times
and its first day at the bourses closed with a market value of $1.11 billion,
making Biocon only the second Indian company to cross the $1-billion mark
on the first day of listing.

She entered into more than 2,200 high-value R&D licensing and other deals
within the pharmaceuticals and bio-pharmaceutical space between 2005 and
2010 and helped Biocon expand its global footprint to emerging and
developed markets through acquisitions, partnerships and in-licensing. Her
belief that healthcare needs can only be met with affordable innovation has
been the driving philosophy that has helped Biocon manufacture and market
drugs cost-effectively.

In 2007-08, a leading US trade publication, Med Ad News, ranked Biocon as

the 20th leading biotechnology companies in the world and the 7th largest
biotech employer in the world. Biocon also received the 2009 BioSingapore
Asia Pacific Biotechnology Award for Best Listed Company.

Today, thanks to her leadership, Biocon is building cutting-edge capabilities,

global credibility and global scale in its manufacturing and marketing
acticities. It has Asia’s largest insulin and statin facilities as also the largest
perfusion-based antibody production facilities.

ACHIEVEMENTS
 Nikkei Asia Prizes- Regional Growth by Nikkiei Inc. (2009)
 Wharton Infosys Business transformation Award (2006)
 Padma Bhusan (2005)
 Honorary Doctrate from Manipal Acadamy of Higher education –
MAHE (2005)
 Life time Acheivement Award from Indian chamber of Commerce
(2005)
 Honorary Doctorate of Science from Ballart Universty (2004)
  The Economic Times Business Women of the year (2004)
 Whirpool GR8 women award for science and technology (2004)
 Australian Alumni High Achiever Award from the IDP Australian
Alumni Association (2003)
 Ernst & Young Entrepreneur of the Year Award in Healthcare &
Life Sciences Category (2002)
 Woman of the Year from the International Women's Association,
Chennai (1998–1999)
 Padma Shri (1989)
 Outstanding Young Person Award by Jaycees (1987)
 Rotary award for the Best Model Employer (1983)
 Outstanding Contribution Award (AWAKE) (1983)
 Gold for Best Woman Entrepreneur, Institute of Marketing
Management (1982)
 India's richest woman with an estimated worth of Rs. 2,100 crore.

OtherActivities
In 2004, she started the Biocon Foundation to conduct health, education,
sanitation, and environment programs for the benefit of the economically
weaker sections of society. The Foundation’s micro-health insurance
program has an enrolment of 70,000 rural members.

Its 7 ARY clinics are located where healthcare facilities are poor and offer
clinical care, generic medicines and basic tests for those who cannot afford
them. Each of the clinics serves a population of 50,000 people living within
a radius of 10 km. All the clinics organize regular general health checks in
remote villages by bringing in physicians and doctors from network
hospitals. Each year, the Foundation touches more than 300,000 lives
through its holistic healthcare approach.

The Foundation also provides mobile medical services, and conducts

preventive health education programmes and free health-care camps.

She helped establish a 1,400-bed cancer care center at the Narayana Health
City campus at Boommasandra, Bangalore, along with Dr. Devi Shetty of
Narayana Hrudayalaya in 2007. Called the Mazumdar Shaw Cancer Centre
(MSCC), it is one of the largest cancer hospitals of its kind, spread as it is
over an area of five lakh square feet. It specializes in head and neck cancer,
breast cancer and cervical cancer.

Market Share
Biocon shares are currently trading at 408.20 as on 24th dec 2010.current
market value of share is Rs. 8,164 cr. Shares of biocon were listed at issue
price of Rs.400.
Biocon went for an IPO to raise Rs 300 crores to fund its huge capital
expansion plans.

Recent Articles
Pfizer, Biocon in $350 million insulin pact
MUMBAI: The world's largest drug manufacturer, Pfizer Inc, has entered into a $350-
million global agreement to market Bangalore-based Biocon's biosimilar versions of
insulin for diabetes treatment.

This is Pfizer's fourth marketing deal with a domestic company — after Aurobindo ,
Claris LifeSciences and Strides Arcolab — and also first biotech deal from India.

Under the agreement, announced on Monday, Pfizer will make upfront payments totaling
$200 million and an additional development and regulatory milestone payments of up to
$150 million which will be linked to sales (of biosimilar insulin) across global markets.
Drug MNCs, faced with slowing sales in their home markets, are aggressively focusing
on emerging markets by entering into such supply agreements.

Pfizer will hold exclusive rights to commercialize insulin products like recombinant
human insulin, Glargine, Aspart and Lispro globally, except in certain markets. It will co-
market the products with Biocon in Germany, India and Malaysia, a joint statement by
the companies said.

Commenting on the alliance , Kiran Mazumdar-Shaw , CMD of Biocon, said: "This is a

significant inflection point in our globalization path. Pfizer and Biocon bring together a
winning combination of marketing , manufacturing and research excellence which can
build a formidable global footprint in diabetes care. Pfizer brings brand strength and an
unrivalled marketing network that will enable Biocon to realize its objective of seeing its
Insulin portfolio have a world-wide presence."

500-bed Mazumdar Shaw Cancer Centre provides

hope
TNN, Jul 18, 2009, 12.08am IST
BANGALORE: Narayana Hrudayalaya's Health City in Bangalore has added another
feather to its cap. A cancer hospital -- christened Mazumdar Shaw Cancer Centre -- has
been set up in the campus, with the promise of bringing quality cancer care to levels of
affordability not seen so far.

The hospital, which started operations two weeks ago, has been named after Kiran
Mazumdar Shaw, CMD of Biocon, who has put in Rs 40 crore into this project. It
currently has 500 beds, but will eventually become a 5-lakh sq ft, 1,400-bed facility,
making it perhaps the world's largest cancer hospital. It will focus on cancer related to
head, neck, breast and cervix, has qualified in-house doctors, and draws medical expertise
from world renowned medical universities like Cornell.

Dr Devi Prasad Shetty, chairman of Narayana Hrudayalaya, said that cancer is the most
common cause of death after cardiovascular disease. Unfortunately cancer is detected at a
late stage, significantly increasing the possibility of mortality.

"Treatment of cancer is extremely expensive. The idea is to compete with government

hospitals in terms of cost and provide affordable treatment to patients," Shetty said. The
treatment cost, he said, would be 50% lower than in regular private hospitals and 10-20%
lower than in Kidwai Memorial Institute of Oncology. About 25% of the patients -- the
poorer ones -- will be provided free treatment, he said.

The cost per patient is expected to be lower for the Shetty-Shaw hospital because of the
large scale of the operations. "More than 5,000 patients are expected to visit the centre
every day," Shetty said.

Stressing on the need to set standards, Dr Anthony Pais, head of the women's oncology
section, said that 45% of the breast cancer surgeries in hospitals are done by surgeons
who have not specialized in breast cancer. "There is a need to aim for standards. And this
Centre will work towards that," he said.

Kiran Mazumdar Shaw, who is said to have given the idea to Dr Shetty to start a cancer
hospital, has donated Rs 40 crore for the hospital. "A much more comprehensive,
research-based treatment protocol is required for a balance between making medical
assistance and developing an effective cancer treatment. The centre will look into
evolving new techniques, early detection, conduct clinical trials and research," she said.